KYMR
Price
$65.99
Change
+$1.72 (+2.68%)
Updated
Dec 3 closing price
Capitalization
4.75B
77 days until earnings call
Intraday BUY SELL Signals
PROK
Price
$2.47
Change
+$0.22 (+9.78%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
321.31M
Intraday BUY SELL Signals
Interact to see
Advertisement

KYMR vs PROK

Header iconKYMR vs PROK Comparison
Open Charts KYMR vs PROKBanner chart's image
Kymera Therapeutics
Price$65.99
Change+$1.72 (+2.68%)
Volume$508.8K
Capitalization4.75B
ProKidney
Price$2.47
Change+$0.22 (+9.78%)
Volume$9.51K
Capitalization321.31M
KYMR vs PROK Comparison Chart in %
View a ticker or compare two or three
VS
KYMR vs. PROK commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KYMR is a Buy and PROK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (KYMR: $64.32 vs. PROK: $2.26)
Brand notoriety: KYMR and PROK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KYMR: 43% vs. PROK: 40%
Market capitalization -- KYMR: $4.75B vs. PROK: $321.31M
KYMR [@Biotechnology] is valued at $4.75B. PROK’s [@Biotechnology] market capitalization is $321.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KYMR’s FA Score shows that 0 FA rating(s) are green whilePROK’s FA Score has 0 green FA rating(s).

  • KYMR’s FA Score: 0 green, 5 red.
  • PROK’s FA Score: 0 green, 5 red.
According to our system of comparison, both KYMR and PROK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KYMR’s TA Score shows that 4 TA indicator(s) are bullish while PROK’s TA Score has 4 bullish TA indicator(s).

  • KYMR’s TA Score: 4 bullish, 2 bearish.
  • PROK’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, KYMR is a better buy in the short-term than PROK.

Price Growth

KYMR (@Biotechnology) experienced а -2.60% price change this week, while PROK (@Biotechnology) price change was +7.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

KYMR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KYMR($4.75B) has a higher market cap than PROK($321M). KYMR YTD gains are higher at: 59.881 vs. PROK (33.728). PROK has higher annual earnings (EBITDA): -157.52M vs. KYMR (-267.03M). KYMR has more cash in the bank: 665M vs. PROK (295M). PROK has less debt than KYMR: PROK (4.42M) vs KYMR (85.7M). KYMR has higher revenues than PROK: KYMR (44.7M) vs PROK (527K).
KYMRPROKKYMR / PROK
Capitalization4.75B321M1,479%
EBITDA-267.03M-157.52M170%
Gain YTD59.88133.728178%
P/E RatioN/AN/A-
Revenue44.7M527K8,482%
Total Cash665M295M225%
Total Debt85.7M4.42M1,940%
TECHNICAL ANALYSIS
Technical Analysis
KYMRPROK
RSI
ODDS (%)
Bearish Trend 6 days ago
76%
Bullish Trend 6 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
84%
Bullish Trend 6 days ago
67%
Momentum
ODDS (%)
Bullish Trend 6 days ago
79%
Bearish Trend 6 days ago
65%
MACD
ODDS (%)
Bullish Trend 6 days ago
71%
Bearish Trend 6 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
81%
Bearish Trend 6 days ago
73%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
N/A
Bearish Trend 9 days ago
81%
BollingerBands
ODDS (%)
N/A
Bullish Trend 6 days ago
70%
Aroon
ODDS (%)
Bullish Trend 6 days ago
83%
Bearish Trend 6 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
KYMR
Daily Signal:
Gain/Loss:
PROK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNWAX91.88N/A
N/A
American Funds New World R1
ASMMX32.02N/A
N/A
Invesco Summit A
MSECX11.15N/A
N/A
Morgan Stanley Inst International Eq C
LVAEX29.92N/A
N/A
LSV Value Equity Investor
BSGSX15.76N/A
N/A
Baird Small/Mid Cap Growth Investor

PROK and

Correlation & Price change

A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RLYB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RLYB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
N/A
RLYB - PROK
45%
Loosely correlated
-0.25%
NRIX - PROK
39%
Loosely correlated
-3.31%
APGE - PROK
38%
Loosely correlated
+0.20%
KYMR - PROK
37%
Loosely correlated
-3.80%
ZYME - PROK
37%
Loosely correlated
-3.57%
More